Hebei Senlang Biotechnology
Dongguan
About Hebei Senlang Biotechnology
Hebei Senlang Biotechnology is focused on the treatment of immune cells new technology development and application of high-tech enterprises.The company has the CAR-T research base (Senrang CAR-T Research Center) in North China, and has formed a high-barrier technology platform such as innovative CAR structural design, virus and cell culture , which can take into account technical research and development, hospital clinical application Provide high-quality and effective cellular immunotherapy support for hematological tumors, solid tumors and other tumor diseases, immune system diseases and other patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $29.6M
- Funding stage: Private Equity
- Last round: Private Equity (May 2022)
- Website: senlangbio.comen
- Phone: +86-311-82970975
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/hebei-senlang-biotechnology-131900 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.